The orally active melanocortin-4 receptor antagonist BL-6020/979: A promising candidate for the treatment of cancer cachexia

R. Dallmann, P. Weyermann, C. Anklin, M. Boroff, K. Bray-French, B. Cardel, I. Courdier-Fruh, H. Deppe, J. Dubach-Powell, M. Erb, R. H. Haefeli, M. Henneböhle, H. Herzner, M. Hufschmid, D. L. Marks, S. Nordhoff, M. Papp, C. Rummey, G. Santos, F. SchärerH. Siendt, M. Soeberdt, L. T. Sumanovski, M. Terinek, C. Mondadori, N. Güven, A. Feurer

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint Dive into the research topics of 'The orally active melanocortin-4 receptor antagonist BL-6020/979: A promising candidate for the treatment of cancer cachexia'. Together they form a unique fingerprint.

Medicine & Life Sciences